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Abstract 
Background: The gold standard for the diagnosis of melanocytic lesions is histologic 
examination. However, as histologic examination can have its limitations, there are many clinical 
scenarios in which additional testing may be appropriate in an attempt to render a definitive 
diagnosis.   
Methods: A literature review for three ancillary tests - comparative genomic hybridization 
(CGH)/ single nucleotide polymorphism (SNP) array, fluorescence in situ hybridization (FISH), 
and gene expression profiling by quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) - was compiled and current use patterns were tabulated. Survey of the practice 
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patterns of these tests by dermatopathologists was also accessed in the attendees of the American 
Society of Dermatopathology Annual Meeting (Chicago, 2016). 
Results: Here we summarize the use of these molecular tests in melanocytic lesions. We found 
that 54.4% of the respondents surveyed utilize (or expect consultants to utilize) molecular testing 
of melanocytic lesions in their practice when appropriate.   
Conclusions: CGH/ SNP arrays, FISH testing and qRT-PCR applied to melanocytic lesions has 
allowed for more accurate classification. Just over half of those surveyed use molecular testing 
for melanocytic lesion with the majority sending their cases out  for completion of the molecular 
test.  
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Introduction 
To help better direct dermatopathologists in their use of ancillary tests the American Society of 
Dermatopathology (ASDP) created the Appropriate Use (AUC) Task Force in 2015. The AUC 
Task Force was divided into four subgroups that each chose to examine 2 to 3 ancillary tests. As 
a part of this effort, a synopsis of the evidence behind each test was performed. 1 The reviews for 
each of the four subgroups are intended to be a review of the literature and highlight the data 
obtained during Short Course I "Best Practices" at the 51st annual meeting of the ASDP. These 
reviews do not have any specific recommendations. The separate manuscript that details the 
evidenced-based criteria to assist ordering professionals in making the most appropriate 
utilizations decisions for specific clinical conditions has now been published. 1   
The Melanocytic Subgroup of the AUC Task Force chose to examine the use of comparative 
genomic hybridization (CGH)/ single nucleotide polymorphism (SNP), fluorescence in situ 
hybridization (FISH), and gene expression profiling by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) in the diagnosis of melanocytic lesions. As a separate 
assessment, the results of a survey of the practice patterns of these tests by dermatopathologists 
attending the ASDP Annual Meeting (Chicago, 2016) is also presented.  
The gold standard for the diagnosis of melanocytic lesions is histologic examination. However, 
as histologic examination can have its limitations, there are many clinical scenarios in which 
additional testing may be appropriate in an attempt to render a definitive diagnosis.  The clinical 
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management and prognosis for the patient depends on the ability to accurately diagnose 
melanocytic lesions.  The Melanocytic Subgroup of the ASDP AUC Task Force chose to explore 
the appropriate use of CGH/ SNP array, FISH, and qRT-PCR assays.    
CGH/ SNP arrays 
CGH is a molecular method that can analyze the entire genomic DNA in cells for copy number 
changes. Two techniques are generally employed. In one, a fluorochrome (usually green) is used 
to label tumor DNA. The labeled DNA is then mixed in a 1:1 ratio with a reference DNA from 
normal tissue that has been labeled with a different fluorochrome (usually red). The mixture is 
subsequently hybridized onto normal metaphase spreads (classic CGH) or hybridized onto a 
microarray of mapped clones of genomic DNA (array CGH; aCGH). The metaphase 
chromosomes or the microarrays are washed and then scanned. A green color at a certain locus 
indicates excess tumor DNA compared to normal and therefore a gain of that region, red color 
indicates a DNA loss and yellow color normal copy number compared to the normal reference.  
In the last decade aCGH has largely replaced classic CGH due to its higher resolution, 
reproducibility and robustness. In a second technique, only tumor DNA is labeled with a reporter 
fluorochrome and hybridized onto a microarray. Similar to the prior protocol the arrays are 
washed and scanned. The copy number status at a certain locus is determined by comparing the 
signal intensity with a reference from a control series of normal tissues. More recently, SNP 
microarray platforms have emerged as alternatives to CGH. SNP platforms are able to provide 
allele frequency data as well as information regarding copy number changes. These platforms 
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can detect copy neutral loss of heterozygosity events and can be designed to identify selected 
mutations. Protocols using molecular inversion probes specifically designed to work with low 
quantities of degraded DNA from formalin-fixed paraffin embedded tissue have been also 
developed in the last years. 2,3 The utility of CGH/ SNP arrays is based on the principle that most 
melanomas to have an unstable genome with numerous chromosomal structural abnormalities 
while the majority of melanocytic nevi do not display chromosomal aberrations or show specific 
isolated abnormalities (such as 11p gains in Spitz nevi). 4,5,6,7 This non-overlapping pattern of 
chromosomal aberrations provided an opportunity for diagnostic strategies based on tests 
evaluating DNA copy number alterations such as CGH / SNP arrays. Figure 1 highlights an 
example of a case where SNP microarray was performed.  
The advantage of CGH/ SNP arrays relies in the ability to provide a global overview of the 
genome. However, CGH may miss changes present only in a small subpopulation of cells. 
Studies have shown that aCGH can reliably detect a clonal aberration when it is present in at 
least 30-40% of the lesion. For these reasons, aCGH is suboptimal in instances when there is 
tumoral heterogeneity or the tumor is admixed with benign elements such as inflammatory cells 
as dilution effect can lead to a false negative result. Another limitation of CGH is the longer 
turnaround time for results (often 2–4 weeks), in comparison with other molecular technologies. 
8,9,10,11,12 
FISH testing 
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FISH is a molecular technique that uses fluorescent DNA locus specific probes to detect 
complementary genomic DNA sequences on metaphase and / or interphase nuclei in tissue 
sections thus allowing for direct visualization of specific genomic DNA segments. Generally 
speaking there are two types of probes that are used for melanocytic lesions: centromere probes 
that identify centromeric regions on chromosomes and locus specific probes that hybridize onto 
target sequences spanning genes or regions of interest. Depending on the type of probe(s), FISH 
assays have the ability to detect chromosomal deletions, amplifications, and translocations. 
Figure 2 highlights an example of a case where FISH and SNP array testing were performed.  
FISH testing has several benefits compared to CGH including the ability to detect changes in 
small subpopulations in a heterogeneous lesion, a faster turnaround time and fewer tissue 
requirements. On the other hand FISH also has a few disadvantages: it can only identify changes 
involving the probed loci resulting in false negative results, interpretation is labor intensive and 
requires specialized expertise and can generate false positive results due to tetraploidy. 13 
qRT-PCR  
qRT-PCR is a technique commonly used in molecular biology to detect the level of expression of 
specific RNA transcripts. Briefly, the technique involves reverse transcription of RNA to 
complementary DNA (cDNA) followed by real-time PCR. Transcriptome data gathered from 
large expression array experiments can be evaluated for significant differences of RNA 
expression between neoplasms and used to develop gene expression signatures capable of 
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differentiating between benign and malignant neoplasms. 14 The Myriad myPath® Melanoma 
gene expression signature test is an example whereby a multivariate gene expression signature 
was developed and then validated on a training cohort of melanocytic neoplasms. The 
differential expression of 23 genes involved in cell differentiation and immune signaling between 
nevi and melanoma forms the basis of the test. 15 This includes one gene specific to melanocytic 
differentiation (PRAME), eight genes implicated in immune signaling (CCL5, CD38, CXCL10, 
CXCL9, IRF1, LCP2, PTPRC, and SLL), five genes with multifunctional roles (S100A9, S100A7, 
S100A8, S100A12 and PI3), and nine housekeeping genes. A proprietary weighted algorithm is 
applied to the expression levels to produce a melanoma diagnostic score (MDS).  A negative 
score (-16.7 to -2.1) suggests a benign diagnosis, a positive score (0.0 to 11.1) suggest a 
malignant diagnosis, and a score between -2 and -0.1 refers to an indeterminante category. An 
advantage of qRT-PCR is that this analysis can detect gene expression changes that may not 
result from gains or losses. 
The scientific evidence behind the use of CGH, FISH, and qRT-PCR for melanocytic lesions in 
dermatopathology was performed, itemized, and summarized.  In addition, an audience response 
system was used at the beginning of Short Course I “Best Practices” at the 53rd annual meeting 
of the ASDP in Chicago, Illinois, to explore the practice patterns of these molecular assays in the 
attendees of the course. 
Materials and Methods 
This article is protected by copyright. All rights reserved.
Evidence Review 
Journals written in English from the years 2000-2016 were searched in PubMed to find and 
assess the use of molecular testing (FISH, CGH and qRT-PCR) in melanocytic neoplasia.  The 
articles were searched using “melanoma”, “melanocytic neoplasm” and “melanocytic 
nevus/nevi” as major key words that were then overlapped with the specific modes of molecular 
testing (FISH, CGH, and qRT-PCR).  Only articles that mostly examined cutaneous melanomas 
were included. Articles dealing with non-cutaneous melanomas (e.g. uveal) were excluded, with 
the exception of anal and conjunctival melanoma. Both case series of fewer than 3 cases and 
individual case reports were excluded in the analysis. Research focusing on melanoma cell lines 
was also excluded.  
Practice Pattern Assessment 
The practice patterns of attendees of Short Course I "Best Practices" during the 53rd Annual 
meeting of the ASDP in Chicago, Illinois for their use of molecular testing in melanocytic 
lesions was evaluated using an audience response system. This was performed via a web-based 
platform (Poll Everywhere) that allows participation via a smartphone, tablet or other internet-
connected device by anyone in the audience. The audience was polled prior to presentation of 
evidence review.  
Comments and Conclusions 
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In the dawn of molecular analysis, the genetic exploration of melanocytic lesions led to the 
discovery that melanomas contain chromosomal gains at 1q, 4q, 6p, 7q, 11q, 17q and 20q, as 
well as chromosomal deletions including 9p, 10, and 21q. Gains in 6p were found to be 
specifically associated with an unfavorable prognosis. Analysis of Spitz nevi highlighted that the 
majority of Spitz nevi do not demonstrate genomic aberrations; about 20% of Spitz nevi show 
gains in 11p. These crucial discoveries provided the foundation for future studies using the 
testing modalities described herein, and the commencement of the use of molecular diagnostic 
tools as an adjunct to histology. The key goals of these tests are to provide more accurate 
characterization of melanocytic lesions and provide some insight in to prognosis. 4,6 This review 
summarizes the scientific evidence related to the use of  CGH/ SNP arrays, FISH and qRT-PCR 
in melanocytic lesions since these pivotal discoveries.  
 
CGH in cutaneous melanocytic lesions since the year 2000 (Table S1) 
Within the literature review, there were 23 articles identified.  The majority of these studies were 
retrospective case series. The number of specimens in the studies ranged from 3 – 186 with a 
total number of 856 tests performed on 254 melanocytic nevi, 74 atypical melanocytic 
proliferations, and 528 melanomas. The melanocytic lesions studied included invasive melanoma 
of all histopathologic subtypes, Spitz tumors, metastatic lesions, deep penetrating nevi, blue nevi, 
and proliferative nodules.  Eleven of these studies explored and compared the difference of CGH 
on nevi and melanoma.   
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Early cytogenetic studies of melanocytic lesions helped provide the rationale behind the utility of 
CGH as an ancillary tool in melanocytic lesions and highlighted the differences between nevi 
and melanoma. Bastian et al. in 2003 applied CGH to 132 melanomas and 54 benign nevi and 
demonstrated that 96.2% of melanomas had some form of genetic abnormality, while none of the 
nevi examined, except Spitz nevi (which can show gains in 11p) had any abnormalities.4 Since 
this discovery, cytogenetic analysis has also been able to differentiate between melanoma 
subtypes and allowed for more accurate classification of melanocytic lesions. Differences 
detected by CGH in acral versus non-acral, mucosal and sun exposed melanomas have 
highlighted the genetic heterogeneity of melanomas. It is now widely accepted that acral 
melanomas have copy number gains in 5p, 11q, 12q and 4q and losses in 6q, and 15q more 
frequently than melanomas at non-acral sites. 5,16 Sun exposed melanoma, namely lentigo 
maligna melanoma, have more frequent losses of chromosomes 17p and 13q.4 Sinonasal 
melanomas have a high frequency of 1q, 6p and 8q gains. 17 Likewise, melanomas that in the 
past did not fit into a traditional classification can now perhaps be better classified. For example, 
melanoma with large nests, a form a melanoma that lacks many other histologic features of 
traditional melanoma, is now regarded as a subtype of superficial spreading melanoma. 18 
Although much is still left to be discovered, cytogenetic studies have also shed light on the 
stepwise progression of melanoma. For instance, in situ melanomas have been shown to have 
fewer abnormalities than invasive melanomas 19 and melanomas that do not develop metastasis 
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have significantly less chromosomal aberrations (P<0.01) compared with melanomas that 
develop metastasis. 20 
Moreover, cytogenetic analysis has emphasized the importance of genetics in prognosis. Hirsch 
et al used cytogenetic analysis on a cohort of melanoma patients stratified into good and poor 
prognosis groups. They showed that melanomas having a good prognosis have less chromosomal 
imbalances than melanomas having a poor prognosis that harbor a larger number of 
chromosomal aberrations, including focal aberrations and chromothripsis. 21 Similarly, it has 
been shows that melanomas with chromosomal gains in 6p and malignant blue nevi with loses of 
3p have a poor prognosis. 22 However, some data shows that not all genetic aberrations affect 
prognosis and one cannot rely on numbers and genetic data alone, and thus it is paramount to 
correlate clinical and histologic findings with molecular results when classifying melanocytic 
lesions. 23,24 
While studies continue to be performed with CGH to identify new aberrations associated with 
melanoma and their effects on prognosis, the literature suggests that CGH is an established 
adjunctive test in the diagnosis of melanoma in various clinical scenarios when a definitive 
diagnosis cannot be rendered.   
   
FISH in cutaneous melanocytic lesions since the year 2000 (Table S2) 
Review of the literature has demonstrated that FISH has the potential to serve as an adjunct to 
morphology and immunohistochemistry in challenging cases. Within the literature, 60 articles on 
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FISH were identified based on the search criteria.  The majority of these studies were 
retrospective case series.  Within a single study, the number of specimens ranged from 3 – 804 
with a total number of 5283 tests performed on 1895 melanocytic nevi, 1398 atypical 
melanocytic proliferations, and 1990 melanomas.  The melanocytic lesions included in the 
studies covered a broad range of melanocytic neoplasms, including spitzoid tumors, ambiguous 
melanocytic lesions, various subtypes of melanoma, metastatic melanoma, dermal 
melanocytosis, proliferative nodules, and conjunctival and anal melanocytic lesions.  Two 
articles specifically included pediatric-aged cases in their series.25,26 
In general, FISH testing for melanoma is a multiplex assay including probes targeting loci that 
have been found to be frequently altered through CGH technology. 27 The clinical utility of FISH 
has been explored in a number of studies. While many studies have evaluated differences 
between nevi and melanoma, there are also an abundance of articles looking at ambiguous or 
controversial lesions. 21,28,29,30,31,32,33,34,35,36,37,38,39 Likewise, studies have confirmed the usefulness 
of FISH in the differentiation of conjunctival nevi from melanoma, 40 epithelioid blue nevi from 
blue nevus-like cutaneous melanoma metastasis 41 and in melanocytic lesions with a large 
epithelioid component. 42 FISH has also been used in the distinction of Spitz nevi from spitzoid 
melanoma.  43 Similarly, the utility of FISH in differentiating nodal nevi from metastatic 
melanoma has been reported. 44  
However, caution must still be used as limitations of this test have been identified. Certain 
melanoma subtypes have a higher rate of false negative FISH results using the standard panel; 
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therefore, more research may be needed to develop probes which yield higher sensitivities. One 
such example is the utility of FISH in distinguishing sclerosing nevi from desmoplastic 
melanoma. A positive FISH result is helpful in confirming melanoma, but a negative result does 
not equate with benignancy. 45 
The standard FISH panel has evolved over time. An initial study, investigated the performance of 
14 FISH probes targeting the loci most commonly altered in melanoma. 27 Using sets of 
unequivocal lesions (benign and malignant) the authors determined that a panel of probes 
targeting 6p25 (RREB1), centromere 6, 6q23 (MYB) and 11q13 (CCND1) provided the highest 
discrimination between the two groups with a sensitivity and specificity of 86.7% and 95.4%, 
respectively. The test uses a scoring algorithm which involves evaluation of at least 30 nuclei 
from lesional cells for the number of probes and records the percentage of nuclei with > 2 signals 
for 6p25 and 11q13 and with less signals for 6q23 compared to centromere 6. The test is 
considered positive if any one of these percentages exceed the validated cutoffs. 21 46,47 Since then 
several studies have examined alternative cut-off levels and used other combinations of probes. 
48 Due to the relative poor performance of the initial FISH panel in the subsets of spitzoid and 
spindle melanomas a second generation of the probe set was developed that included probes for 
9p21 (CDKN2A) and 8q24 (MYC). 49 It has been proposed that adding these probes to the 
original probe set increases sensitivity to 94% and specificity to 98% for these lesions. In 
addition, it has been proposed that this probe set provides prognostic information in borderline 
spitzoid tumors. 50 It should be noted that these values have not yet been replicated in large 
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subsequent studies so -as with all new ancillary test in diagnostic pathology- these may be 
judged with caution at this point in time. 
Overall the literature shows a relatively high sensitivity and specificity for FISH with the 
sensitivity ranging from 85-100% and the specificity ranging from 90-98%.  The variation is due 
to the probe set used for the assay and the cut-off thresholds set. These ranges are significantly 
lower for ambiguous lesions, where the sensitivity and specificity are 43-100% and 33-89%, 
respectively.  While it is clear when reviewing the literature that FISH is not able to give a 
definitive answer of benign or malignant, it does appear that in certain clinical scenarios, FISH 
may be informative as an ancillary study.   
The prognostic significance associated with FISH in melanocytic lesions has also been studied. 
In looking at paired primary and metastatic melanomas, primaries that were FISH positive had a 
higher rate of metastasis and melanoma-associated deaths compared with FISH negative cases, 
though in this study only the primary melanoma was studied with FISH. 51 Research has shown 
that gains in 11q13 and 8q24 are thought to be predictive of metastasis. 52 Likewise, in a study 
examining atypical spitzoid tumors with borderline histology, cases with homozygous losses of 
9p21, gains in 6p25 or 11q13 were at a higher risk for aggressive clinical behavior compared to 
atypical spitzoid tumors that were FISH-negative or had isolated 6q23 deletions that did not 
show clinical progression. 53 
 
qRT-PCR in cutaneous melanocytic lesions (Table S3) 
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Within the literature, there were 4 articles on qRT-PCR for review.  The studies included a case 
series, a validation, a validation with a prospective cohort, and a prospective cohort.  Within a 
single study, the number of specimens ranged from 117 – 1695 with a total number of 3,649 tests 
performed on 2,001 melanocytic nevi, 481 atypical melanocytic proliferations, and 1,167 
melanomas.   
The two validation studies suggest qRT-PCR has a sensitivity of 90-91.5% and a specificity of 
91-92.5% for melanoma. 25, 54 In one study there was 97 and 83% concordance with histology for 
FISH and qRT-PCR in a group of unequivocal melanocytic lesions resulting in a sensitivity and 
specificity of 93 and 100% for FISH and 62 and 95% for qRT-PCR. The inter-test agreement 
was found to be 80%. 55 In another study, for diagnostically challenging cases initially diagnosed 
as indeterminate by histomorphology and IHC, definitive diagnoses increased by 56.6% 
following qRT-PCR testing. 56 As the literature for qRT-PCR is in its infancy, future studies will 
likely dictate the utility and clinical scenarios where this ancillary test may be helpful.  
 
Practice Patterns of FISH, CGH, and qRT-PCR in cutaneous melanocytic lesions (Table 1) 
To identify the practice patterns of CGH, FISH, and qRT-PCR an audience response system was 
used to survey attendees of Short Course I “Best Practices” during the 53rd annual meeting of the 
ASDP (Chicago, Illinois, 2016).  The number of respondents ranged from 167 and 176 for each 
question related to molecular testing of melanocytic lesions.  It is difficult to provide a precise 
overview of the expertise level of these participants and “expertise” certainly has an element of 
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subjectivity. This could be considered a limiting factor in the interpretation of the results. But 
given the nature of this subspecialty conference it can be assumed that the vast majority were 
practicing dermatopathologists or dermatopathologists in training. Fifty-four percent of 
respondents reported routine use (or expecting consultants to use) of molecular testing for 
ambiguous melanocytic lesions with an additional 37% reporting rare use (less than five time 
each year) while only 8% of respondents never used molecular testing for this scenario.  Not 
surprisingly, only 31% of respondents reported performing molecular testing at their practice or 
institution, with an additional 59% report using outside labs to perform these tests.   This likely 
reflects the technical difficulty in performing these assays and the fact that qRT-PCR is generally 
only available as a send out test.  
 
While cost is not a factor when creating AUC, more than half (54%) of respondents report 
‘almost always’ considering insurance or patient-related costs prior to ordering molecular testing 
for melanocytic lesions and only 27% rarely consider cost.  Since cost is a significant factor in 
ordering these ancillary studies, criteria that identify clinical scenarios where testing improves 
diagnosis and outcomes with a high degree of specificity and sensitivity will be helpful to 
practicing dermatopathologists. 
 
To reiterate, this article is intended to be a review of the literature and highlight the data obtained 
during Short Course I "Best Practices" at the 51st annual meeting of the ASDP. This review does 
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not have any specific recommendations. As the work of the AUC task force of the ASDP 
continues, appropriateness ratings to better help guide dermatopathologists in the selection of 
these tests in commonly encountered scenarios in clinical practice will be reported.  
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Figures and Tables 
Figure 1. Biopsy from a 32-year old woman with a lesion on the face. A. Low-power H&E: 
Predominantly dermal melanocytic proliferation accompanied by epidermal hyperplasia. B. 
High-power H&E: Melanocytes infiltrate through a sclerotic stroma and have large nuclei with 
vesicular chromatin, prominent nucleoli and abundant eosinophilic cytoplasm imparting a 
spitzoid morphology. Few mitotic figures are noted (black arrow). C. SNP array: Top panel 
represents the copy number changes and shows a gain of chromosome 11p with no additional 
abnormalities (black arrow). Bottom panel represents the allele ratio and demonstrates a 
corresponding allele imbalance at 11p (red arrow). The findings are consistent with a 
desmoplastic Spitz nevus. 
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Figure 2. Biopsy from the right forearm of a 33-year old man. A. Low-power H&E: Dermal 
melanocytic proliferation with the appearance of a cellular blue nevus. A hypercellular nodule is 
noted (arrow).  B. High-power H&E: Nodule composed of cytologically atypical epithelioid cells 
with conspicuous nucleoli and sheet-like growth pattern. C. FISH: A probe for 6p25 (RREB1 
gene) shows more than 2 copies in the majority of nuclei (80%) supporting a diagnosis of 
melanoma. D. SNP array: Top panel illustrates the copy number changes and confirms the gain 
of 6p (arrow). Additional gains of 11p, 11q, 13q, 20 and 21 and losses pf 9q, 10p, 11p and 11q 
can be identified on the SNP array. Bottom panel represents the B-allele frequency and shows 
corresponding allele imbalances at affected loci. The findings are consistent with a melanoma 
arising in a cellular blue nevus. 
 
Table 1: Practice patterns of attendees of the ASDP Annual Meeting (Chicago, 2016) for CGH, 
FISH and qRT-PCR in melanocytic neoplasms. 
 
Audience response questions Answer Choices Number of 
respondents (%) 
How often do you consider 
insurance issues or patient related 
costs before ordering molecular 
testing for melanocytic lesions? 
Almost always 90 (53.9)  
More than half of the time 17 (10.2) 
Less than half of the time 15 (9.0) 
Rarely 45 (27.0) 
Do you use molecular testing in 
your practice (or expect your 
consultants to utilize) when 
appropriate? 
Yes 93 (54.4) 
Rarely (less than 5 times a year) 64 (37.4) 
Never 14 (8.2) 
Do you perform molecular testing at 
your practice/institution? 
Yes 54 (30.7) 
No, but I send out for it to be performed 103 (58.5) 
No, because I do not use the procedure/test 19 (10.8) 
 
This article is protected by copyright. All rights reserved.
  
 
 
 
 
 
Supporting Information 
The online version of this article has additional supporting information. 
Table S1: Evidence review table for the use of CGH in melanocytic lesions. 
Table S2: Evidence review table for the use of FISH in melanocytic lesions. 
Table S3: Evidence review table for the use of qRT-PCR in melanocytic lesions. 
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